Overview

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The current most important topical treatments for psoriasis are vitamin D3 analogues and/or corticosteroids. The possibility of another effective treatment for psoriasis could be based on the immunosuppressive efficacy of selective blockers of a lymphocyte potassium channel. The aim of the clinical trial is to evaluate the safety, tolerability and anti-psoriatic efficacy of topical SPS4251 formulations in comparison to placebo and to a marketed topical Vitamin-D analogue ointment in a psoriasis plaque test.
Phase:
Phase 1
Details
Lead Sponsor:
Circassia Limited
Collaborator:
Bioskin GmbH
Treatments:
Calcipotriene